Sunho Biologics (HKSE:02898) Debt-to-Asset : 0.05 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics Debt-to-Asset?

Sunho Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$27.12 Mil. Sunho Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$4.96 Mil. Sunho Biologics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was HK$632.35 Mil. Sunho Biologics's debt to asset for the quarter that ended in Jun. 2024 was 0.05.

Sunho Biologics Debt-to-Asset Historical Data

The historical data trend for Sunho Biologics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunho Biologics Debt-to-Asset Chart

Sunho Biologics Annual Data

Trend

Dec22

Dec23

Dec24

Debt-to-Asset

0.03

0.07

Sunho Biologics Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Asset	-	-	0.03	0.05	0.07

Competitive Comparison of Sunho Biologics's Debt-to-Asset

For the Biotechnology subindustry, Sunho Biologics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunho Biologics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunho Biologics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sunho Biologics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Sunho Biologics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sunho Biologics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.382	+	7.543)	/	317.688
	=	0.03

Sunho Biologics's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(27.119	+	4.956)	/	632.347
	=	0.05

Sunho Biologics (HKSE:02898) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sunho Biologics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sunho Biologics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunho Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN

Website

http://www.sunho-bio.com.cn

Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.

Executives

Sunho Fortune Investments Limited	2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited	2301 Trustee
Zhang Feng	2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited	2101 Beneficial owner

Sunho Biologics Headlines

No Headlines